期刊
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
卷 15, 期 -, 页码 -出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/17588359231183679
关键词
antibody-drug conjugates; breast cancer; targeted therapy
类别
Antibody-drug conjugates (ADCs) are a type of antineoplastic agents that combine monoclonal antibodies, cytotoxic payloads, and linkers to create a smart drug delivery system with high specificity and potency. ADCs are internalized by tumor cells and release cytotoxic payloads, leading to cell death. The development of ADCs with additional functional properties allows for activity in neighboring cells without the target antigen, providing a valuable strategy to overcome tumor heterogeneity. Several ADCs have been approved for breast cancer treatment, demonstrating unprecedented efficacy. However, challenges still exist, including the need for reliable biomarkers, management of toxicities, understanding resistance mechanisms, and optimizing treatment sequencing and combinations.
Antibody-drug conjugates (ADCs) are a class of antineoplastic agents whose structure is composed of three main components: a monoclonal antibody (mAB) targeting a specific target antigen, a cytotoxic payload, and a linker binding the antibody to the payload. By combining the specificity of mABs with the high potency of the payloads, ADCs constitute a smart drug delivery system with improved therapeutic index. After recognition and binding of the mAB to its target surface antigen, ADCs are internalized by endocytosis by the tumor cell, releasing the payloads into the cytoplasm, where they exert their cytotoxic activity, eventually leading to cell death. The composition of some of the new ADCs confers additional functional properties that allow expanding their activity to neighboring cells not expressing the target antigen, constituting a valuable strategy to overcome tumor heterogeneity. Some of these 'off-target effects', such as the bystander effect, are possibly the mechanism underlying the antitumor activity demonstrated in patients with low expression of the target antigens, which represents an important paradigm shift in anticancer targeted therapy. Three ADCs are currently approved for the treatment of breast cancer (BC); two anti-HER2 (human epidermal growth factor receptor 2) ADCs (trastuzumab emtansine and trastuzumab deruxtecan); and one Trop-2-targeted ADC (sacituzumab govitecan). Based on the unprecedented efficacy data demonstrated by these agents, ADCs have been incorporated as part of standard regimens for all subtypes of advanced BC, as well as for high-risk early HER2-positive BC. Despite the remarkable advances, several hurdles still remain to overcome, including the development of reliable biomarkers for patient selection, prevention, and management of potentially severe toxicities, ADC resistance mechanisms, post-ADC resistance patterns, and optimal treatment sequencing and combinations. In this review, we will summarize the currently available evidence related to the use of these agents, as well as explore the current landscape of ADC development for BC treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据